Skip to content
Technology
Pipeline
News
Press
People
Partners
Careers
Contact
Menu
Technology
Pipeline
News
Press
People
Partners
Careers
Contact
Endogena Therapeutics holds investor call and gives update on Retinitis Pigmentosa Clinical Trial
Zürich, Switzerland, February 7, 2024
Listen to a testimonial from one of our principal investigators Dr. Victor Gonzalez.
Prev
Previous
Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment
Next
Matthias Steger was invited to present at the Ophthalmology Innovation Summit (OIS) on May 4th, 2024, in Seattle,Washington, US.
Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
